Advances and Applications of Regulatory Genomics in Multiple Myeloma

Dear Colleagues,

This Special Issue, " Advances and Applications of Regulatory Genomics in Multiple Myeloma ", will mainly focus on the study and application of the several layers of genetic regulation that are fundamental for multiple myeloma development, progression, extramedullar disease, resistance and relapse. Accordingly, this knowledge opens up the opportunity for novel and specific tools for diagnostics, prognostics and therapy.

Multiple myeloma is extremely complex and heterogeneous. The interplay between genetic alteration and epigenetic changes have been the subject of intense research, not only within the scope to better understand the disease, but also to provide new tools that can directly impact the lives of myeloma patients.

We invite authors to submit original research and review articles that focus on the biological functions and therapeutic potential of regulatory genomics in multiple myeloma. Potential topics include, but are not limited to:

• Defining and characterising the myeloma and myeloma bone marrow’s microenvironment epigenome and its changes during disease progression:
• The correlation between genetic and epigenetic alterations to define myeloma subgroups;
• The role of non-coding genome in myeloma development and progression;
• The role of microRNA in myeloma development and progression;
• The role of epigenetic regulation in myeloma plasticity;  
• Epi-drugs and their application in myeloma therapy;
• Recent advances in epigenetic biomarkers for their use in diagnostics, patients’ stratification and prognosis;
• Use of epigenetic/gene-regulatory drugs for target resistance and relapse (pharmacological, immune or cellular therapy);
• Single-cell multi-omics approaches to define gene-regulatory networks

Dr. Valentina S. Caputo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• myeloma
• epigenetics
• non-coding genome
• relapse
• progression
• plasticity
• multi-omics
• DNA-methylation
• miRNA
• lncRNA
• chromatin structure
• genome dynamics
• epi-drugs